Catheter Precision (VTAK) Liabilities and Shareholders Equity (2017 - 2026)

Catheter Precision (VTAK) has reported Liabilities and Shareholders Equity for 10 consecutive years, with $35.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 41.47% year-over-year to $35.1 million; the TTM figure through Mar 2026 stood at $76.5 million (up 45.57% YoY), while the FY2025 annual figure was $15.9 million, down 42.89% from the prior year.
• Liabilities and Shareholders Equity climbed to $35.1 million in Q1 2026 per VTAK's latest filing, from $15.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $48.5 million in Q1 2023 and bottomed at $109000.0 in Q2 2025.
• Historically, Liabilities and Shareholders Equity has averaged $25.9 million across 5 years, with a median of $26.6 million in 2024.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity surged 104.27% — and 2025, when it sank 42.89%.
• Catheter Precision's Liabilities and Shareholders Equity stood at $16.8 million in 2022, then jumped by 82.56% to $30.7 million in 2023, then fell by 9.65% to $27.8 million in 2024, then slumped by 42.89% to $15.9 million in 2025, then surged by 121.22% to $35.1 million in 2026.
• Business Quant data shows VTAK's Liabilities and Shareholders Equity at $35.1 million in Q1 2026, $15.9 million in Q4 2025, and $25.5 million in Q3 2025.